keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/28319621/resolution-of-psoriatic-lesions-on-the-gingiva-and-hard-palate-following-administration-of-adalimumab-for-cutaneous-psoriasis
#1
John K Brooks, Justin W Kleinman, Charlotte E Modly, John R Basile
We report the case of a 51-year-old man who presented with an atypical inflammatory response of the gingiva and hard palate that was concomitant with widespread cutaneous psoriasis. The patient had discontinued taking adalimumab 6 months prior to presentation, having achieved satisfactory management of his cutaneous lesions; however, he resumed 2 days prior to presentation due to recurrent disease. A gingival biopsy was consistent with oral psoriasis. At a 2-month follow-up, dramatic resolution of oral involvement was evident and the cutaneous psoriatic plaques were greatly reduced in size...
February 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28319617/biosimilars-in-psoriasis-the-future-or-not
#2
Roselyn Kellen, Gary Goldenberg
As patents for the biologic agents reach their expiration dates, dermatologists must prepare for the coming of biosimilars. These agents have been deemed "highly similar" to their reference products in a process outlined by the US Food and Drug Administration (FDA). In 2016, the FDA approved 3 biosimilars for various indications including plaque psoriasis and psoriatic arthritis. However, biosimilars are not the same as small-molecule generics because they have a complex manufacturing process that makes it impossible to produce identical products to their reference products...
February 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28319289/clinical-characteristics-of-psoriasis-in-inflammatory-bowel-diseases-patients
#3
L Pescitelli, M Gianotta, F Ricceri, L Lazzeri, M Milla, F Prignano
Crohn's Disease (CD) and Ulcerative Colitis (UC) account for most cases of Inflammatory Bowel Diseases (IBD). These diseases share common genetic abnormalities and pathogenic mechanisms with other immune-mediated diseases including Psoriasis (Pso) [1, 2]. A recent study investigating specifics Pso characteristics in IBD patients (phenotype, severity) revealed that in IBD patients the frequency of plaque-type Pso, nail Pso, Psoriatic Arthritis and severe Pso seems to be lower compared with non-IBD patients [3]...
March 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28319281/successful-secukinumab-treatment-of-generalized-pustular-psoriasis-and-erythrodermic-psoriasis
#4
C Mugheddu, L Atzori, A Lappi, M Pau, S Murgia, F Rongioletti
Erythrodermic psoriasis (EP) and generalized pustular psoriasis (GPP) are the most severe forms of psoriasis, resulting in significant morbidity and even mortality (1) . There are few evidence-based data on their treatment (2,3) . Secukinumab, a fully human anti-IL-17A monoclonal antibody, demonstrated strong efficacy in treating moderate to severe plaque-type psoriasis (4,5) . This article is protected by copyright. All rights reserved.
March 20, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28317328/evaluating-dosage-optimality-for-tofacitinib-an-oral-janus-kinase-inhibitor-in-plaque-psoriasis-and-the-influence-of-body-weight
#5
M M Hutmacher, K Papp, S Krishnaswami, K Ito, H Tan, R Wolk, H Valdez, C Mebus, S T Rottinghaus, P Gupta
Tofacitinib is an oral Janus kinase inhibitor. An integrated analysis was conducted to evaluate dosage optimality for tofacitinib in patients with moderate-to-severe plaque psoriasis and the impact of body weight on optimality in this patient population. Data were pooled from one phase IIb trial (2, 5, and 15 mg twice daily (b.i.d.)) and four phase III trials (5 and 10 mg b.i.d.). A longitudinal exposure-response model for Psoriasis Area and Severity Index (PASI) improvement (percent change from baseline) was established...
March 20, 2017: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/28301619/two-multicenter-randomized-double-blind-parallel-group-comparison-studies-of-a-novel-enhanced-lotion-formulation-of-halobetasol-propionate-0-05-versus-its-vehicle-in-adult-subjects-with-plaque-psoriasis
#6
David Pariser, Michael Bukhalo, Scott Guenthner, Steven Kempers, Stephen Shideler, Linda Stein Gold, Eduardo Tschen, Jim Berg, Mary Beth Ferdon, Syd Dromgoole
<p>BACKGROUND: A novel lotion formulation of halobetasol propionate, 0.05% (HBP Lotion) with enhanced vehicle characteristics of a cream while preserving the ease of use and cosmetic elegance of a lotion has been developed to treat plaque psoriasis. OBJECTIVE: Determine the safety and effectiveness of HBP Lotion in patients with plaque psoriasis. METHODS: Two prospective, randomized, vehicle-controlled clinical studies were conducted in 443 adult subjects with moderate-severe plaque psoriasis...
March 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28301617/patient-preference-for-dosing-frequency-based-on-prior-biologic-experience
#7
Mingliang Zhang, Chureen Carter, William H Olson, Michael P Johnson, Susan K Brennem, Seina Lee, Kamyar Farahi
BACKGROUND: There is limited research exploring patient preferences regarding dosing frequency of biologic treatment of psoriasis. METHODS: Patients with moderate-to-severe plaque psoriasis identified in a healthcare claims database completed a survey regarding experience with psoriasis treatments and preferred dosing frequency. Survey questions regarding preferences were posed in two ways: (1) by likelihood of choosing once per week or 2 weeks, or 12 weeks; and (2) by choosing one option among once every 1-2 or 3-4 weeks or 1-2 or 2-3 months...
March 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28301614/a-phase-2-multicenter-double-blind-randomized-vehicle-controlled-clinical-study-to-assess-the-safety-and-efficacy-of-a-halobetasol-tazarotene-fixed-combination-in-the-treatment-of-plaque-psoriasis
#8
Jeffrey L Sugarman, Linda Stein Gold, Mark G Lebwohl, David M Pariser, Binu J Alexander, Radhakrishnan Pillai
<p>BACKGROUND: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Treatment options focus on relieving symptoms, reducing inflammation, induration, and scaling, and controlling the extent of the disease. Topical corticosteroids are the mainstay of treatment, however long-term safety remains a concern, particularly with the more potent formulations. Combination therapy with a corticosteroid and tazarotene may improve psoriasis signs at a lower corticosteroid concentration providing a superior safety profile...
March 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28300921/porokeratosis-ptychotropica
#9
Ana Carolina Franco Tebet, Tatiana Gandolfi de Oliveira, Anna Rita Ferrante Mitidieri de Oliveira, Fabiolla Sih Moriya, Jayme de Oliveira, Luiz Carlos Cucé
Porokeratosis is a skin disorder clinically characterized by annular plaques with keratotic borders resembling the Great Wall of China and histopathologically by cornoid lamellae. The disease has several clinical variants. Porokeratosis ptychotropica, which has recently become part of these variants, is quite rare and little known. The entity is characterized by verrucous plaques - which may resemble a psoriasis plaque - that affect the regions of the buttocks, most commonly the gluteal cleft, with or without extremity involvement...
September 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28299442/interleukin-il-18-cooperatively-with-il-23-induces-prominent-inflammation-and-enhances-psoriasis-like-epidermal-hyperplasia
#10
Noriko Shimoura, Hiroshi Nagai, Susumu Fujiwara, Haruki Jimbo, Takayuki Yoshimoto, Chikako Nishigori
The interleukin (IL)-23/IL-17 axis is strongly implicated in the pathogenesis of psoriasis. Previous studies showed that IL-18 was elevated in early active and progressive plaque-type psoriatic lesions and that serum or plasma levels of IL-18 correlated with the Psoriasis Area and Severity Index. However, the mechanism whereby IL-18 affects disease severity remains unknown. In this study, we investigated the effects of IL-18 on a psoriasis-like skin inflammation model induced by recombinant mouse IL-23. We found that IL-18, cooperatively with IL-23, induced prominent inflammation and enhanced psoriasis-like epidermal hyperplasia...
March 15, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/28291552/clinical-similarity-of-biosimilar-abp-501-to-adalimumab-in-the-treatment-of-patients-with-moderate-to-severe-plaque-psoriasis-a-randomized-double-blind-multicenter-phase-iii-study
#11
Kim Papp, Herve Bachelez, Antonio Costanzo, Peter Foley, Melinda Gooderham, Primal Kaur, Joanna Narbutt, Sandra Philipp, Lynda Spelman, Jolanta Weglowska, Nan Zhang, Bruce Strober
BACKGROUND: ABP 501 is a biosimilar of adalimumab. OBJECTIVE: We sought to compare the efficacy and safety of ABP 501 with adalimumab. METHODS: This 52-week, double-blind study randomized patients with moderate to severe psoriasis to ABP 501 or adalimumab. At week 16, those with 50% or more improvement in Psoriasis Area and Severity Index score from baseline on ABP 501 continued the same treatment, whereas adalimumab-treated patients were rerandomized to adalimumab or ABP 501...
March 10, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28290979/orbital-cellulitis-in-a-psoriatic-patient-treated-with-adalimumab
#12
Vienna G Katana, Robert J Carpenter, John P Trafeli, Julia M Kwan
INTRODUCTION: Psoriatic patients on tumor necrosis factor alpha inhibitors (TNFi) may be at increased risk for upper respiratory tract infections, including chronic rhino-sinusitis (CRS). Rarely, CRS can progress to orbital cellulitis (OC), an emergent ophthalmic complication wherein respiratory flora from paranasal sinus disease intrude the retro-orbital space. MATERIALS AND METHODS: Single case report. RESULTS: We report the first case, to our knowledge, of an invasive sinusitis that rapidly evolved into OC in a patient receiving adalimumab treatment for plaque psoriasis and psoriatic arthritis...
March 2017: Military Medicine
https://www.readbyqxmd.com/read/28288981/nice-recommends-ixekizumab-for-persistent-severe-plaque-psoriasis
#13
Susan Mayor
No abstract text is available yet for this article.
March 12, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28288790/establishment-of-the-first-who-international-standard-for-etanercept-a-tnf-receptor-ii-fc-fusion-protein-report-of-an-international-collaborative-study
#14
Meenu Wadhwa, Chris Bird, Paula Dilger, Peter Rigsby, Haiyan Jia, Marie Emmanuelle Behr Gross
Etanercept, a recombinant human tumor necrosis factor (TNF) receptor Fc fusion protein is an effective treatment option in adults with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis and paediatrics with juvenile idiotypic arthritis and plaque psoriasis. Patent expiration in Europe and intense development of various etanercept products worldwide triggered a need for an international reference standard to facilitate determination of biological activity. Therefore, three candidate preparations of etanercept were lyophilized and evaluated in a multi-centre collaborative study comprising twenty eight laboratories from 15 countries for their suitability to serve as an international standard for the bioactivity of TNF receptor II Fc fusion proteins (international nonproprietary name, Etanercept)...
March 10, 2017: Journal of Immunological Methods
https://www.readbyqxmd.com/read/28280914/differentiation-of-pityriasis-rubra-pilaris-from-plaque-psoriasis-by-dermoscopy
#15
N E Abdel-Azim, S A Ismail, E Fathy
Pityriasis rubra pilaris (PRP) and plaque psoriasis (PP) are two distinctive erythemato-squamous skin diseases that often have to be differentiated from each other and from other similar dermatoses. Dermoscopy has been proven to aid the clinical diagnosis of several inflammatory disorders, minimizing the need for skin biopsy. Our aim was to determine the dermoscopic patterns of PRP compared to PP and to assess the significance of certain dermoscopic criteria in the diagnosis of PRP. This case-control study included 11 patients with biopsy proven PRP and 25 patients with biopsy proven plaque psoriasis...
March 9, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/28280308/evaluation-of-psoriasis-patients-attitudes-toward-benefit-risk-and-therapeutic-trade-offs-in-their-choice-of-treatments
#16
Lina Eliasson, Anthony P Bewley, Farhan Mughal, Karissa M Johnston, Andreas Kuznik, Chloe Patel, Andrew J Lloyd
OBJECTIVE: Treatment options for psoriasis offer trade-offs in terms of efficacy, convenience, and risk of adverse events. We evaluated patients' preferences with respect to benefit-risk in the treatment of psoriasis. METHODS: A discrete choice experiment was conducted in adults from the UK with moderate-to-severe psoriasis using an orthogonal design with 32 hypothetical choice sets. Participants were randomly assigned to one of two surveys with 16 choice sets. Patients' preferences were investigated with respect to the following attributes: reduction in body surface area affected by psoriasis, treatment administration (frequency and mode of delivery), short-term diarrhea or nausea risk, and 10-year risk of developing melanoma or nonmelanoma skin cancer, tuberculosis, or serious infections...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28276777/apremilast-for-the-management-of-moderate-to-severe-plaque-psoriasis
#17
Ramya Vangipuram, Ali Alikhan
Psoriasis is a chronic inflammatory skin disease characterized by erythematous plaques on extensor surfaces, scalp, and back. Current therapies for psoriasis are limited by route of administration, side effects, and cost. Apremilast is the first oral phosphodiesterase inhibitor approved for moderate-to-severe plaque psoriasis. It is a small molecule inhibitor of phosphodiesterase-4, and decreases the inflammatory activity associated with psoriasis. Areas covered: This review will discuss the pharmacology of apremilast, mechanism of action, results from key clinical trials, and its use in managing psoriasis...
February 17, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28274164/impact-of-immunogenicity-on-response-to-anti-tnf-therapy-in-moderate-to-severe-plaque-psoriasis-results-of-the-predir-study
#18
Mariano Ara-Martín, Pedro Herranz Pinto, Dora Pascual-Salcedo
PURPOSE: This study was conducted to examine the relationship between loss of clinical response to anti-tumor necrosis factor (TNF) therapy and the production of anti-drug antibodies (ADAs) and the potential effects of biologic immunogenicity. MATERIALS AND METHODS: This observational, non-interventional, cross-sectional study included patients with moderate-to-severe plaque psoriasis and secondary failure of adalimumab, etanercept and infliximab who were seen in the clinical practice setting...
March 8, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28273375/characteristics-of-patient-receiving-ustekinumab-compared-with-secukinumab-for-treatment-of-moderate-to-severe-plaque-psoriasis-nationwide-results-from-the-dermbio-registry
#19
A Egeberg, L Iversen, R Gniadecki, L Hvid, T N Dam, L E Bryld, L Skov
BACKGROUND: While safety and efficacy of ustekinumab and secukinumab, monoclonal antibodies approved for psoriasis, are described in clinical trials, data on their real-life application are lacking. OBJECTIVE: We compared the characteristics of patients initiating first-time treatment with secukinumab or ustekinumab. METHODS: All Danish patients with moderate-to-severe plaque psoriasis treated with biologics are recorded in the nationwide DERMBIO registry...
March 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28272075/the-impact-of-topical-saint-john-s-wort-hypericum-perforatum-treatment-on-tissue-tumor-necrosis-factor-alpha-levels-in-plaque-type-psoriasis-a-pilot-study
#20
P Mansouri, S Mirafzal, P Najafizadeh, Z Safaei-Naraghi, M H Salehi-Surmaghi, F Hashemian
CONTEXT: Psoriasis is an inflammatory disorder, formed by inappropriate interaction of T lymphocytes with keratinocytes, and consequent eruption of immune responses. High concentrations of tumor necrosis factor-alpha (TNFα) are found in the skin lesions and plasma of patients with psoriasis. Hypericum perforatum, a phytomedicine that has both anti-inflammatory and antiproliferative properties, has been recently reported to be clinically helpful for improvement of psoriatic lesions. AIMS: The aim of the present study was to investigate the effects of topical H...
March 3, 2017: Journal of Postgraduate Medicine
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"